Skip to main content

Day: January 26, 2021

Saga Furs Oyj bokslutskommuniké 1.11.2019–31.10.2020

Saga Furs Oyj bokslutskommuniké 26.1.2021 kl 15.55Coronapandemins negativa inverkan på Saga Furs Oyj:s förmedlingsförsäljning minskade under den andra halvårsperioden – räkenskapsperiodens resultat dock klart förlustbringandeDetta är ett sammandrag av den bokslutskommuniké som Saga Furs Oyj har publicerat. Bokslutskommunikén i sin helhet finns som bilaga till detta meddelande samt på bolagets internetsidor www.sagafurs.com.Coronapandemins negativa inverkan på Saga Furs Oyj:s förmedlingsförsäljning minskade under den andra halvårsperioden – räkenskapsperiodens resultat dock klart förlustbringandeUnder räkenskapsperioden 1.11.2019–31.10.2020 minskade värdet på Saga Furs Oyj:s förmedlingsförsäljning med 47 procent jämfört med föregående räkenskapsperiod och var 157 miljoner euro (2018/2019: 297 milj. euro).Antalet förmedlade skinn och prisnivån...

Continue reading

Aditxt Secures $5 Million Financing to Scale AditxtScore™ Operational Capacity

Balance Sheet Further Strengthened by Receipt of Additional $3.3 Million from Exercise of Existing WarrantsMountain View, CA, Jan. 26, 2021 (GLOBE NEWSWIRE) —  via NewMediaWire — Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has entered into a securities purchase agreement in connection with a financing with an institutional investor (the “Investor”). Upon the closing of the financing, after taking into account an original issue discount and other transaction fees, the Company expects to receive approximately $4.5 million of net cash proceeds, which will be used to launch and scale the Company’s AditxtScore™ immune monitoring...

Continue reading

Atico Continues to Expand Footprint with High Grade Copper-Gold Intercepts Reporting 34.1g/t Au, 112 g/t Ag and 11% Cu over 3 meters at La Plata Project, Ecuador

VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) is pleased to report on the last results of its 2020 drilling program at the La Plata precious metals-rich volcanogenic massive sulphide (“VMS”) project in Ecuador. These results continue to report very encouraging intercepts of volcanic massive sulfides while the new 2021 drill campaign begins in Ecuador.La Plata Drilling Highlights Include:True widths are dependent on uncertainties in the local strike and dip of the mineralization and are estimated to be between 76% and 83% of the drill intercept.Drill holes CMLP-20-146 & CMLP-20-150 were both drilled outside of the existing resource polygon. Drilling was performed to test the “Guatuza extension” of the North Block as it shows continuity...

Continue reading

Indberetning af Morten Hübbe (CEO) og Lars Bondes (COO) tildeling af Tryg-aktier

Koncernchef Morten Hübbe har fået tildelt 15.349 Tryg-aktier til en samlet værdi på 3.155.754 DKK og koncerndirektør Lars Bonde har fået tildelt 7.481 Tryg-aktier til en samlet værdi på 1.538.094 DKK i henhold til matching shares-programmet fra 2017.For yderligere detaljer, se vedhæftning.Vedhæftet fil2021.01.26 Handelsindberetning, Morten Hübbe og Lars Bonde

Continue reading

Victory Square Technologies Portfolio Company, Immersive Tech, Hires Former Senior Executive of the ‘The VOID’, Steven Dooner to lead UNCONTAINED Franchise Development

“Steven Dooner is an exceptional executive…with experience spanning over 40-years, from the inception of Chuck E. Cheese franchise scale in the mid 70’s to senior positions launching many of Disney’s LBE initiatives including a $1.5B Tokyo Disney park expansion, he is a literal Guru in the industry and we couldn’t be more thrilled to have him on our team.” – Immersive Tech’s CEO, Tim BieberVANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors, including digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Fantasy 360 Technologies Inc. DBA Immersive Tech (“Company”)...

Continue reading

Bioanalytical Systems, Inc., to Report First Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, February 9, 2021

WEST LAFAYETTE, Ind., Jan. 26, 2021 (GLOBE NEWSWIRE) — Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that the Company will issue its financial results press release for the fiscal 2021 first quarter ended December 31, 2020, on Tuesday, February 9, 2021, after the close of the stock market, and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.Interested parties may participate in the call by dialing:(877) 407-9753 (Domestic)(201) 493-6739 (International)The live conference call webcast will be accessible in the Investors section of the Company’s website, and directly via the following link:https://78449.themediaframe.com/dataconf/productusers/bas2/mediaframe/43273/indexl.htmlFor...

Continue reading

Everi Announces Selected Preliminary Fourth Quarter 2020 Results in Connection With Opportunity to Reprice a Portion of Its Outstanding Debt

LAS VEGAS, Jan. 26, 2021 (GLOBE NEWSWIRE) — Everi Holdings Inc. (NYSE: EVRI) (“Everi” or the “Company”), a premier provider of land-based and digital casino gaming products, financial technology and player loyalty solutions, today announced selected preliminary financial results for the fourth quarter and full year ended December 31, 2020, in connection with an opportunity to take advantage of favorable market conditions to lower its cost of debt by repricing $735.5 million of its First Lien Term Loan due 2024. While the expected results demonstrate sequential improvement, the preliminary 2020 fourth quarter results reflect continued impact from the COVID-19 pandemic and related casino closures.The Company expects 2020 fourth quarter consolidated revenues to be in a range of approximately $117 million to $121 million reflecting...

Continue reading

Simmons First National Corporation Reports 2020 Earnings

PINE BLUFF, Ark., Jan. 26, 2021 (GLOBE NEWSWIRE) — Simmons First National Corporation (NASDAQ: SFNC) (the “Company” or “Simmons”), parent company of Simmons Bank, today announced net income of $254.9 million for the year ended December 31, 2020, compared to $237.8 million for 2019, an increase of $17.0 million, or 7.2%. Diluted earnings per share were $2.31 for 2020, a decrease of $0.10 or 4.2%, compared to the prior year. Included in the 2020 results were $9.4 million in net after-tax merger-related, early retirement program and net branch right-sizing costs and the gains on the sales of branches in Texas and Colorado. Excluding the impact of these items, core earnings were $264.3 million for the year ended December 31, 2020, compared to $269.6 million for 2019, a decrease of $5.3 million, or 2.0%. Core diluted earnings per share...

Continue reading

BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders. The merger reunites the teams at BridgeBio and Eidos and allows BridgeBio to deploy its full clinical and commercial infrastructure to support the development and global commercialization plans underway for Eidos’ acoramidis, a potential best-in-class therapy for patients with transthyretin (TTR) amyloidosis (ATTR). BridgeBio’s mission is to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.